-
公开(公告)号：EP4292654A2
公开(公告)日：2023-12-20
申请号：EP23189057.5
申请日：2015-09-11
申请人： Board of Regents of the University of Texas System , Amprion, Inc. , Jara, Claudio Soto , Shahnawaz, Mohammad , Lebovitz, Russell M. , Vollrath, Benedikt K.
IPC分类号： A61P25/28
摘要： Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer s Disease, Parkinson s Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
-
公开(公告)号：EP4292654A3
公开(公告)日：2024-01-03
申请号：EP23189057.5
申请日：2015-09-11
申请人： Board of Regents of the University of Texas System , Amprion, Inc. , Jara, Claudio Soto , Shahnawaz, Mohammad , Lebovitz, Russell M. , Vollrath, Benedikt K.
摘要： Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer s Disease, Parkinson s Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
-
公开(公告)号：EP3191599A4
公开(公告)日：2018-03-14
申请号：EP15839278
申请日：2015-09-11
申请人： UNIV TEXAS , AMPRION INC , JARA CLAUDIO SOTO , SHAHNAWAZ MOHAMMAD , LEBOVITZ RUSSELL M , VOLLRATH BENEDIKT K
CPC分类号： G01N33/6896 , G01N2800/52
摘要： Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
-
公开(公告)号：EP3191599A1
公开(公告)日：2017-07-19
申请号：EP15839278.7
申请日：2015-09-11
申请人： Board Of Regents Of the University Of Texas System , Amprion Inc. , Jara, Claudio Soto , Shahnawaz, Mohammad , Lebovitz, Russell M. , Vollrath, Benedikt K.
CPC分类号： G01N33/6896 , G01N2800/52
摘要： Methods and kits are provided for amplifying and detecting misfolded proteins from samples, for example, from patients having Alzheimer's Disease, Parkinson's Disease, and the like. For example, a method for determining a presence of soluble, misfolded protein in a sample may include contacting the sample with a monomeric, folded protein to form an incubation mixture; conducting an incubation cycle two or more times effective to form an amplified portion of misfolded protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded protein; physically disrupting the incubation mixture effective to break up at least a portion of any protein aggregate present; and determining the presence of the soluble, misfolded protein in the sample by detecting at least a portion of the soluble, misfolded protein. The monomeric, folded protein and the soluble, misfolded protein may exclude prion protein (PrP) and isoforms thereof.
摘要翻译： 提供了用于扩增和检测来自样品的错折叠蛋白质的方法和试剂盒，所述样品例如来自患有阿尔茨海默病，帕金森氏病等的患者。 例如，用于确定样品中可溶性错误折叠蛋白质存在的方法可以包括使样品与单体折叠蛋白质接触以形成温育混合物; 进行孵育循环两次或更多次，以形成错误折叠蛋白质的扩增部分; 温育有效引起至少一部分单体折叠蛋白质的错误折叠和/或聚集的温育混合物; 物理破坏温育混合物有效破碎存在的任何蛋白质聚集体的至少一部分; 并通过检测至少一部分可溶性错误折叠蛋白质来确定样品中可溶性错误折叠蛋白质的存在。 单体折叠蛋白和可溶性错折叠蛋白可能不包括朊病毒蛋白（PrP）及其同种型。
-
-
-
搜索结果
4 条记录 (耗时 0.01 秒)
